Compare SPSC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPSC | ATAI |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2009 | 2025 |
| Metric | SPSC | ATAI |
|---|---|---|
| Price | $74.78 | $7.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $96.80 | $15.88 |
| AVG Volume (30 Days) | 578.2K | ★ 17.4M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.59 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $220,566,000.00 | $4,089,000.00 |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | $7.37 | N/A |
| P/E Ratio | $103.65 | ★ N/A |
| Revenue Growth | 14.11 | ★ 1227.60 |
| 52 Week Low | $49.04 | $3.27 |
| 52 Week High | $117.32 | $7.26 |
| Indicator | SPSC | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 67.62 | 73.26 |
| Support Level | $73.05 | $3.89 |
| Resistance Level | $78.33 | N/A |
| Average True Range (ATR) | 2.97 | 0.04 |
| MACD | 0.51 | -0.08 |
| Stochastic Oscillator | 81.66 | 91.67 |
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. The company has one operating segment Supply Chain Management Solutions, that derives revenues from customers by providing access to cloud-based supply chain management services, primarily under subscription-based service arrangements.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.